Qualitek Labs cash falls to Rs 15.41 lakh after capex spending

Qualitek Labs Limited ended the half year to 30 September 2026 with standalone cash and cash equivalents of Rs 15.41 lakh, down from Rs 2.0208 crore at 31 March 2026. Investing outflows of Rs 19.2682 crore and higher receivables outweighed Rs 2.482 crore of operating cash generation and Rs 14.9195 crore of financing inflows.

Why did Qualitek Labs’ cash balance fall?

Qualitek Labs’ cash balance fell because its Rs 19.2682 crore investment outflow exceeded the combined Rs 17.4015 crore generated from operating and financing activities in the half year ended 30 September 2026. Cash and cash equivalents declined by Rs 1.8667 crore from an opening balance of Rs 2.0208 crore to Rs 15.41 lakh at the reporting date.

The closing cash-equivalent balance comprised Rs 90,000 in cash on hand and Rs 14.51 lakh in current-account balances. It excludes Rs 17.60 lakh of other bank balances, reported separately within current assets, compared with Rs 11.86 lakh at 31 March 2026. The cash-flow statement uses the indirect method prescribed under Accounting Standard 3, or AS-3, Cash Flow Statements.

How did operating cash flow compare with profit?

Qualitek Labs generated Rs 2.482 crore of operating cash despite reporting profit before tax of Rs 6.355 crore for the half year ended 30 September 2026. Operating profit before working-capital changes was Rs 12.0421 crore after including Rs 2.8353 crore of depreciation, Rs 2.4266 crore of interest on loans and Rs 40.80 lakh of gratuity and leave-encashment provisions.

Working-capital movements reduced the cash conversion from that operating profit. Trade receivables increased by Rs 8.7806 crore, loans and advances rose by Rs 1.2083 crore, and other current assets increased by Rs 33.76 lakh. These outflows were partly offset by a Rs 2.1059 crore increase in trade payables, Rs 33.41 lakh in other current liabilities and a Rs 9 lakh inventory reduction; income tax paid net of refunds was Rs 1.767 crore.

The balance sheet records trade receivables of Rs 28.4603 crore at 30 September 2026, up from Rs 19.7042 crore at 31 March 2026. Inventories fell to Rs 26.63 lakh from Rs 35.63 lakh over the same period. The receivables movement was therefore the largest disclosed working-capital use of cash, rather than inventory accumulation.

What did Qualitek Labs spend on expansion?

Qualitek Labs used Rs 19.2682 crore in investing activities in the six months to 30 September 2026, principally Rs 13.996 crore for capital work-in-progress and Rs 4.6322 crore for property, plant and equipment. A further Rs 91.88 lakh was a net outflow on long-term loans given or recovered, while other non-current assets increased by Rs 39.12 lakh.

Capital advances generated Rs 72.24 lakh of cash and interest received contributed Rs 49,000, but neither offset the principal investment spending. For the year ended 31 March 2026, investing outflows totalled Rs 38.7165 crore, including Rs 31.9064 crore for capital work-in-progress and Rs 6.126 crore for property, plant and equipment. The latest half-year outflow was lower than the prior full-year amount.

The asset balances reflect the spending during the September half year. Property, plant and equipment rose to Rs 56.4361 crore from Rs 49.9204 crore, while capital work-in-progress increased to Rs 60.6236 crore from Rs 41.9181 crore. Intangible assets declined to Rs 2.1326 crore from Rs 2.3905 crore, and non-current investments remained Rs 39.9906 crore at both dates.

How did Qualitek Labs fund its cash needs?

Qualitek Labs reported a Rs 14.9195 crore financing cash inflow, led by a Rs 15.5129 crore increase in short-term borrowings during the half year. It also availed Rs 4.1616 crore of long-term borrowings, while repayments of long-term borrowings, finance-lease principal and interest totalled Rs 4.7949 crore.

Short-term borrowings stood at Rs 31.7491 crore on 30 September 2026, compared with Rs 16.2361 crore on 31 March 2026. Long-term borrowings increased to Rs 51.4679 crore from Rs 48.7558 crore. Together, the two balance-sheet borrowing categories rose by Rs 18.2251 crore to Rs 83.217 crore over the six months.

Other current liabilities increased to Rs 15.9827 crore from Rs 7.0544 crore, and trade payables to creditors other than micro and small enterprises rose to Rs 6.4871 crore from Rs 4.3968 crore. Short-term provisions moved in the opposite direction, declining to Rs 36.51 lakh from Rs 2.3879 crore. Standalone finance cost was Rs 2.6141 crore, versus Rs 1.5874 crore for the half year ended 31 March 2026.

What funding plan is awaiting BSE approval?

Qualitek Labs is awaiting BSE Limited’s in-principle approval for a proposed preferential issue of up to Rs 20.016 crore in equity shares and up to Rs 26.964 crore in fully convertible warrants. The board approved the proposals on 22 September 2026, and shareholders approved them at an extraordinary general meeting on 16 October 2026.

The proposed equity issue covers up to 386,000 shares at Rs 518.55 each, including a premium of Rs 508.55 per share. The proposed 520,000 warrants, also priced at Rs 518.55 each, are to persons or entities in the promoter and promoter group. Warrant holders may convert in one or more tranches within 18 months from allotment into an equivalent number of fully paid equity shares.

Management said net proceeds would be used for expansion of existing laboratories, laboratory acquisitions in new territories or segments, working capital and general corporate purposes. Qualitek Labs reported one business segment, Testing and Inspection Services, and one geographic segment, within India. Standalone revenue from operations was Rs 44.7208 crore for the half year ended 30 September 2026, compared with Rs 38.6175 crore for the half year ended 31 March 2026.

Conclusion

Qualitek Labs’ September 2026 standalone cash flow shows that Rs 2.482 crore of operating cash did not cover Rs 19.2682 crore of investment spending, particularly Rs 13.996 crore for capital work-in-progress and Rs 4.6322 crore for property, plant and equipment. Receivables increased by Rs 8.7806 crore, while higher borrowings helped fund the resulting cash requirement.

The next disclosed matter to watch is BSE Limited’s in-principle approval for the proposed Rs 20.016 crore share issue and up to Rs 26.964 crore of convertible warrants. Management has identified laboratory expansion, acquisitions, working capital and general corporate purposes as uses of the proceeds, and warrant conversion may occur within 18 months of allotment.